532 results about "Inflammatory bowel disease" patented technology

The invention relates to a bifidobacterium animalis subsp. Lactis B7 as well as a composition and application thereof, and belongs to the technical field of microorganisms, the bifidobacterium animalis subsp. Lactis B7 is preserved in the China Center for Type Culture Collection on April 19, 2024, and the preservation number is CCTCC NO: M2024734. The bifidobacterium animalis subsp. Lactis B7 is named as Bifidobacterium animalis subsp. Lactis B7, the composition is named as Bifidobacterium animalis subsp. Lactis B7, and the composition is named as Bifidobacterium animalis subsp. Lactis B7. The invention also discloses application of the B7 fermentation composition in preparation of medicines for preventing and treating ulcerative colitis, constipation and constipation-type ulcerative colitis. According to the bifidobacterium animalis subsp. Lactis B7, high-yield short-chain fatty acid and indolepropionic acid are achieved, sulforaphane is generated through glucoraphanin, intestinal tract movement is improved, ulcerative colitis or inflammatory bowel disease activity index DAI and weight loss caused by the disease activity index DAI are effectively relieved, mouse colon injury is remarkably relieved, and mucosa layers are protected; the effects of resisting inflammation, inhibiting pathogenic bacteria and improving the intestinal barrier function are achieved.

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

The invention discloses an attenuated artificial bear gall powder nano preparation, the physical structure of which is a core-shell structure, the core is zinc oxide nanoparticles, the shell is mesoporous SiO2, and artificial bear gall powder is attached to the outer surface of the shell, through the design of the core-shell structure, the dissolution of zinc ions can be reduced while efficient loading and pH response release of the artificial bear gall powder can be realized, and the toxicity of the artificial bear gall powder can be reduced. The toxicity of the preparation is reduced; the invention further discloses a preparation method which has the characteristics of simple steps, low cost and suitability for industrial production. The invention further discloses a novel application range, namely, the compound has a wide clinical application prospect in the fields of inflammatory bowel diseases and the like needing targeted anti-inflammatory treatment.

The invention discloses a mucosal epithelial cell targeted oral ROS response type nano-enzyme as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The oral ROS response type nano-enzyme comprises Ce-CDs carbon dots and a betaine polymer, and the betaine polymer is coated on the surfaces of the Ce-CDs carbon dots to form nano-particles; the Ce-CCDs carbon dots are prepared by taking a metal cerium source and chlorogenic acid as raw materials through a pyrolysis method. Through structural innovation and function integration, the prepared nano-enzyme shows outstanding advantages in the aspects of catalytic activity, targeted delivery, collaborative treatment, industrial application and the like, a new technical scheme is provided for efficient and safe treatment of inflammatory bowel diseases, and the nano-enzyme has remarkable technical innovation and clinical application value.

This invention discloses a system for predicting the efficacy of inflammatory bowel disease based on multimodal data, relating to the field of medical information processing. The system includes: a multimodal data acquisition module for receiving multimodal data; a text feature extraction module for determining text feature vectors using a text feature extraction model; an endoscopic intestinal mucosal feature recognition module for determining intestinal mucosal features using an endoscopic intestinal mucosal feature recognition model; an image feature recognition module for determining imaging features using an image feature recognition model; a pathological feature extraction module for determining pathological features using a pathological recognition model; and an efficacy prediction module for predicting the efficacy of biologics based on multimodal data features using a Transformer model and fully connected layers. Compared to existing technologies, this invention achieves efficacy prediction of biologics based on the fusion of clinical, pathological, endoscopic, and imaging multimodal features, improving the accuracy and clinical rationality of diagnostic and treatment decisions.

The invention discloses a non-invasive intestinal flora fixed-point sampling and drug release device, and belongs to the technical field of micro-ecological diagnosis and treatment. The device comprises a shell, an internal storage bin, a medicine loading cavity and a channel switching mechanism. The shell adopts a capsule-shaped design, and an enteric coating is arranged on the surface of the shell, so that the function is started after the shell reaches a specified position of an intestinal tract. Through the internal ingenious mechanism linkage design, the device can firstly complete non-invasive fixed-point sampling of intestinal contents, and after the sampling action is completed, a drug release mechanism is automatically triggered, so that accurate drug delivery of the same part is realized. Cooperative operation of sampling and drug release in time sequence and space is achieved, and the problems of pain, disjunction of the diagnosis and treatment process, poor drug targeting and the like caused by traditional invasive operation are effectively solved. The device is flexible in structural design, has the advantages of being noninvasive, efficient, accurate in time sequence control and the like, and is suitable for integrated application of diagnosis and treatment of various digestive tract diseases such as inflammatory bowel disease management, micro-ecological regulation and the like.

The invention discloses a bacterial cluster motion single image detection method and system based on deep learning, and the method and system are used for quickly and automatically distinguishing the states of cluster motion, swimming and the like of bacteria. According to the method, high-precision classification is realized by acquiring a long-exposure single blurred image of bacteria in a circular limited space and extracting spatial-temporal characteristics by using a dense connected neural network (DenseNet) with an attention module. The kit is suitable for a high-throughput environment, can be integrated into portable equipment, and is used for early diagnosis and treatment evaluation of diseases such as urinary system infection (UTI) and inflammatory bowel disease (IBD).

The invention relates to the technical field of microorganisms, and discloses Ackermann muciniphila, a combined microbial agent thereof and application of the Ackermann muciniphila in inflammatory enteritis. The invention provides Akkermansia muciniphila AIML-559, and the preservation number of the Akkermansia muciniphila AIML-559 is CGMCC (China General Microbiological Culture Collection Center) No. 34246. The invention relates to a combined microbial agent, which is characterized by comprising Ackermann muciniphila AIML-559 and Bifidobacterium adolescentis AIML-528 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.34300). The combined microbial agent is prepared from the following raw materials: Ackermann muciniphila AIML-559 and Bifidobacterium adolescentis AIML-528 The ackermann mucophil combined microbial inoculum is suitable for treatment intervention of inflammatory bowel disease (IBD), and can relieve weight loss, hemolysis, anemia, diarrhea, intestinal bleeding and other symptoms of IBD mice.

The present invention relates to a fermentation product obtained by a fermentation process of at least one bacterial strain in the presence of at least one vegetable extract. The fermentation product of a bacterial may comprise alimentary and / or pharmaceutically acceptable components or comprised in medical food or nutritional composition. The fermentation product and is useful for the treatment and / or prevention of inflammatory diseases, in particular, inflammatory bowel disease.

The present invention provides a pharmaceutical composition having an effective dose of a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof for treating inflammatory bowel disease. Disclosed is a pharmaceutical composition for treating inflammatory bowel disease, which comprises a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof, where the compound or the pharmaceutically acceptable salt thereof is administered to a human at a dose of 50 mg or more per day as an active ingredient, where R represents a hydroxyl group or an isobutoxy group.

The invention discloses multi-component inulin hydrogel as well as a preparation method and application thereof, and belongs to the technical field of nano materials and medicines.The multi-component inulin hydrogel is characterized in that a medicine L-alanyl-L-glutamine contributing to intestinal mucosa repair is entrapped in the inulin hydrogel; the multi-component inulin hydrogel has the advantages that the multi-component inulin hydrogel is prepared from the inulin and composite nanoparticles (namely mesoporous polydopamine-gallium composite nanoparticles) composed of an active oxygen scavenger polydopamine and an antibacterial agent gallium ions, the repairing capacity on intestinal barriers is further enhanced, and the prepared multi-component inulin hydrogel can be used for effectively treating inflammatory bowel diseases and non-alcoholic steatohepatitis.

The invention relates to the technical field of medical instruments, in particular to a multi-mode biological feedback ear vagus nerve self-adaptive stimulation device and method.The device comprises a host, a stimulation electrode, a signal collection bracelet and an electroencephalogram collection module, and the host comprises core hardware configuration and a power management system; the signal acquisition bracelet comprises an ECG module, a PPG module, a GSR module, a six-axis acceleration sensor and the like. The ear vagus nerve stimulation parameter can be dynamically adjusted through real-time analysis of multi-mode data such as electrocardio, electroencephalogram, heart rate variability, respiration-heart rate synchronism and emotional state, personalized precise treatment is achieved, meanwhile, the wearing comfort and the durability of the device are improved, and the application range is wide. The traditional Chinese medicine composition can be used for auxiliary treatment of various diseases such as inflammatory bowel disease, epilepsy, chronic insomnia, depression, chronic pain, anxiety disorder, post-traumatic stress disorder and autonomic nerve dysfunction, and the functions of a nervous system are adjusted and the symptoms of a patient are improved by accurately stimulating the vagus nerve in the auricular concha area.

The invention discloses a lactobacillus paracasei strain with an effect of relieving inflammatory bowel diseases and application thereof, and belongs to the technical field of microbial fermentation. The strain is Lactobacillus paracasei JGSLP08, and the preservation number of the Lactobacillus paracasei JGSLP08 is CGMCC (China General Microbiological Culture Collection Center) NO.34274. The invention further discloses a preparation method of the Lactobacillus paracasei JGSLP08. The strain has the characteristics of strong acid resistance, bile salt resistance and gastrointestinal fluid resistance, can effectively inhibit salmonella typhimurium, escherichia coli and staphylococcus aureus, and has an excellent antioxidant effect. A DSS-induced colitis mouse model shows that the lactobacillus paracasei can effectively improve the DIA score of a mouse, regulate inflammatory factors, reduce oxidative stress injury, relieve inflammatory cell infiltration and protect the integrity of mucosal epithelium, so that the inflammatory bowel disease is relieved and / or treated.

According to the application disclosed by the invention, the new lactobacillus rhamnosus LR159 is found for the first time, and the strain can be used for effectively treating the inflammatory bowel disease by inhibiting the inflammation level, recovering the barrier function of intestinal mucosa and regulating and improving the intestinal microenvironment. Compared with known lactobacillus rhamnosus, the LR159 strain provided by the invention has better intestinal colonization ability, and can realize more lasting anti-inflammatory and mucous membrane repair effects by breaking through the limitation of pathological microenvironment of the inflammatory bowel disease, thereby enhancing the treatment effect of the inflammatory bowel disease. In conclusion, the lactobacillus rhamnosus LR159 has a great application prospect in preventing and treating the inflammatory bowel disease.

The invention discloses a preparation method of compound lactobacillus fermented asparagus yoghurt, and belongs to the technical field of food biotechnology and microbial fermentation. The lactobacillus fermented asparagus yoghurt is prepared by taking asparagus primary pulp and fresh cow milk as raw materials, and mixing, fermenting and ripening the raw materials by adopting the lactobacillus paracasei JGSLP08 and the lactobacillus pentosus JGS34, and the obtained compound lactobacillus fermented asparagus yoghurt has excellent antioxidant activity and high-dose lactobacillus viable count; meanwhile, the traditional Chinese medicine composition has a remarkable prevention and treatment effect on inflammatory bowel diseases. The lactobacillus fermented asparagus yoghurt can be widely applied to the field of preventing and / or treating inflammatory bowel diseases, in particular to preparation of food for preventing and / or treating inflammatory bowel diseases.

Provided herein are variant α4β7 integrin antibodies and methods of use.

The invention relates to an adipose-derived stem cell and exosome composition for mucosal inflammation and an application of the adipose-derived stem cell and exosome composition. The composition is composed of a hybrid nano-vesicle and a pulsatilla chinensis exosome compound in a mass ratio of 1: 1. The hybrid nanovesicles are prepared by fusing adipose-derived stem cell exosomes and lipidosome and modifying honey polysaccharide, and the pulsatilla chinensis exosome compound is loaded with interleukin 23 peptidomimetic, polyethylene glycol, black scale quantum dots and camptothecin. The composition has the functions of efficient anti-inflammation, immunoregulation, precise targeting and tissue repair, and meanwhile, the curative effect is enhanced through photo-thermal synergistic treatment. The preparation method comprises the steps of exosome extraction by a density gradient centrifugation method, liposome fusion and surface modification. The composition is suitable for treating mucosal inflammation such as inflammatory bowel disease and oral mucositis, has the advantages of high stability, good biocompatibility and the like, and provides a safe and effective novel treatment strategy for clinic.

Various embodiments are provided relating to caninized, feline, or equine antibodies that bind canine, feline, and / or equine IL23 and / or TNFα, including bispecific antibodies that bind both IL23 and TNFα. Such antibodies may be used alone or in combination in methods for treating canine, feline, and / or equine subjects with inflammatory conditions, such as inflammatory bowel disease (IBD), osteoarthritis, and inflammatory conditions such as gastroenteritis in dogs and cats.

The invention discloses an inflammatory bowel disease classification method and system based on deep learning. The method comprises the following steps: acquiring an original RGB image of an enteroscope; constructing a classification model based on a convolutional neural network; inputting an original colonoscope RGB image into a backbone network of the classification model, generating a space attention graph through multi-stage cascade processing of a convolution unit and a double-branch statistics-receptive field attention module, and inputting the space attention graph into a cross-stage attention fusion module; an original colonoscope RGB image is input into an endoscope depth-of-field feature extractor, and the endoscope depth-of-field feature extractor extracts multiple pieces of depth-of-field information of the colonoscope and inputs the depth-of-field information into a multi-scale visual Transform encoder; the cross-stage attention fusion module utilizes a dynamic feature fusion mechanism, combines a multi-scale visual Transform encoder, and dynamically weights and fuses the space attention map and Transform features to generate global features. According to the technical scheme, the visual features and the anatomical structure features of the enteroscopy image are fused, and the recognition precision is improved.

Disclosed herein are compositions and methods for the treatment of inflammatory bowel disease. According to some embodiments, the compositions and methods involve the use of a delayed-release capsule formulation containing a mesalamine layer, a hyaluronan layer, and at least one coating layer.

This paper discusses a strain of Bifidobacterium animalis subsp. lactis B7 and its composition and applications, belonging to the field of microbial technology. The specific strain is Bifidobacterium animalis subsp. lactis B7. Bifidobacterium animalis subsp. lactis Bifidobacterium lactis subspecies B7 was deposited at the China Center for Type Culture Collection on April 19, 2024, with accession number CCTCC NO: M2024734. This invention also discloses the application of the B7 fermentation composition in the preparation of drugs for the prevention and treatment of ulcerative colitis, constipation, and constipation-predominant ulcerative colitis. This animal bifidobacterium lactis subspecies B7 produces high levels of short-chain fatty acids and indolepropionic acid, utilizes sulforaphane to generate sulforaphane, increases intestinal peristalsis, effectively alleviates the disease activity index (DAI) and weight loss caused by ulcerative colitis or inflammatory bowel disease, significantly reduces colonic damage in mice, protects the mucosal layer, has anti-inflammatory effects, inhibits pathogens, and improves intestinal barrier function.

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

To provide: a technique that can predict the prognosis of inflammatory bowel disease, can contribute to verifying treatment effects at that point in time, imposes less physical burden, and has high accuracy (low likelihood of missing individuals at risk of worsening disease); and a technique that can contribute to diagnosing inflammatory bowel disease, imposes less physical burden, and enables inexpensive and rapid testing of the likelihood of contracting inflammatory bowel disease.SOLUTION: A method for predicting the prognosis of inflammatory bowel disease comprises detecting the amount of an N-acetylneuraminate lyase gene derived from intestinal bacteria in a biological sample from a subject. A method for testing inflammatory bowel disease comprises detecting the amount of an N-acetylneuraminate lyase gene derived from intestinal bacteria in a biological sample from a subject.SELECTED DRAWING: Figure 6

The invention relates to a novel polypeptide and application thereof. The polypeptide provided by the invention is short in peptide chain and faster and better in absorption. Experimental results show that the polypeptide provided by the invention shows an obvious enteric cavity dilatation relieving effect in pharmacodynamic tests of a zebra fish inflammatory bowel disease model and a rat inflammatory bowel disease model. The polypeptide provided by the invention has a remarkable colitis relieving effect, and can be used for preparing a medicine for treating enteritis, especially a medicine for treating ulcerative colitis.

A method for treating inflammatory bowel disease using prolyl hydroxylase domain-containing protein (PHD) inhibitors and additional agents is described herein.

The invention relates to a microbial single-cell gelation encapsulation method based on aloe gel and application, the method realizes single-cell gelation encapsulation through electrostatic interaction of sterile aloe gel and intestinal anaerobic bacteria (such as Agathobacter rectasis), and the method comprises the specific steps of aloe gel preparation, bacterial suspension culture and oscillation mixing to form a stable structure. The preparation method has the advantages that the acid resistance and biocompatibility of the natural aloe gel are utilized to replace a traditional synthetic material, so that the gastrointestinal tolerance of thalli is improved; meanwhile, the synergistic effect of aloe active ingredients (such as aloe-emodin) and intestinal bacterial metabolites (butyric acid) is combined, so that the anti-inflammatory and intestinal steady-state regulation and control effects are enhanced. Experiments show that the survival rate of the encapsulated bacteria in simulated gastric juice within 4 hours is larger than or equal to 90%, the intestinal colonization rate is effectively increased compared with naked bacteria, the inflammatory factor level of a colitis model mouse can be remarkably reduced, and a safe and efficient new strategy is provided for micro-ecological treatment of inflammatory bowel diseases.

The invention provides a polysubstituted aromatic amine compound (as shown in a general formula I) as well as a preparation method, a pharmaceutical composition and application thereof, and particularly provides a compound with a structure as shown in the general formula I as well as an optical isomer, a medicinal salt or a mixture of the compound and the optical isomer. The compound has good IRAK4 inhibitory activity, so that the compound can be used for treating, preventing and relieving IRAK4 target related diseases, especially for treating autoimmune diseases such as arthritis, inflammatory bowel disease and the like, malignant tumors such as leukemia and the like or other related diseases.

This invention provides a multi-omics diagnostic model for inflammatory bowel disease (IBD), along with its biomarker screening method, applications, and reagent kits. Currently, there is no gold standard for diagnosing IBD, leading to many unidentifiable suspected cases in clinical practice. This invention utilizes information on the abundance of gut bacteria, the functional genes of gut bacteria, and the content of intestinal metabolites to establish a predictive model for IBD. Furthermore, this invention integrates the above two types of omics information and the prediction across three information dimensions to establish a predictive model with impressive predictive capabilities. The method and model of this invention can assist in the diagnosis and differentiation of IBD.